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Meningococcal disease is rare in Mauritius; only one case was
reported from 1992 to 1999. However, since June 2000, four
cases have occurred. Epidemiologic information and typing
results indicate that these recent cases probably followed the
introduction of Neisseria meningitidis W135 in Mauritius by pil-
grims returning from the Hajj in 2000 and 2001. 
auritius is a small tropical island in the Indian Ocean
(population 1.2 million). The country is classified as a
middle-income country by the World Bank; its primary com-
mercial links are with Europe, the Indian subcontinent, and
southern Africa.
Bacteriologic investigations for government health institu-
tions in Mauritius are conducted in only one laboratory. These
centralized results indicate that meningococcal disease is
extremely rare in Mauritius. From 1992 to 1999, the only
recorded infection occurred in a patient 3 days after he
returned from the United Kingdom. However, since June
2000, four cases of meningococcal disease have occurred in
Mauritians who have no history of travel outside the island.
Case Reports
Case 1
In June 2000, a 49-year-old Muslim woman was admitted
to the hospital with a purpuric rash. She was initially thought
to have a hematologic disorder before meningococcal septice-
mia was suspected. Despite treatment with intravenous peni-
cillin and cefotaxime, she died the following day. Neisseria
meningitidis was isolated from her blood cultures. A latex
agglutination test with polyvalent reagent was positive for
groups ACYW135 (Wellcogen bacterial antigen kit, Murex,
Dartford, UK), but negative results were obtained with
monovalent sera for group A, B, and C antigens (Slidex,
Biomérieux, Marcy l’Etoile, France). The isolate was subse-
quently typed by the World Health Organization (WHO) Col-
laborating Centre for Meningococcal Infections in Marseilles,
where it was confirmed as N. meningitidis serogroup W135,
type 2a, subtype 1.2,5.  It belonged to ST-11, the same
sequence type as isolates obtained from English and French
pilgrims returning from the Hajj that same year (1). The
patient had no history of travel or close contact with a return-
ing pilgrim, according to relatives.
Case 2
In July 2000, a 5-year-old Muslim child was admitted to
the hospital with fever, vomiting, and ecchymoses. Initially
she was thought to have a bleeding disorder. She had already
received intravenous amoxicillin when meningococcal disease
was suspected and specimens for microbiologic investigation
taken. Her cerebrospinal fluid (CSF) was turbid with a leuko-
cyte count of 11,500 per µL. CSF was positive for N. meningit-
idis antigens, groups ACYW135 with polyvalent serum, and
negative for Haemophilus influenzae type b, pneumococcus,
and meningococcus groups A, B, and C. Cultures of CSF and
blood were negative. Cefotaxime was added to her treatment,
and she made a good recovery. 
The child’s father, who returned from the Hajj 3 months
earlier, had received the meningococcus A+C bivalent vaccine
before travel. He had not been clinically ill during the pilgrim-
age or after his return. 
Case 3
In November 2000, a 27-year-old man was admitted to the
hospital with ecchymoses and signs and symptoms of menin-
gitis. He had received antibiotics before investigations were
performed. His CSF was turbid, with 26,000 leukocytes and
10,000 red cells per µL. Results of antigen testing on blood
and CSF specimens were similar to those of the child in case 2,
and cultures were negative. He was treated with cefotaxime
and fully recovered. The patient was not Muslim and had not
had close contact with a returning pilgrim. However, he and
the patient in case 1 lived in the same village (population
10,000) as 22 pilgrims from the 2000 Hajj.
Case 4
In April 2001, a 4-month-old Muslim infant was hospital-
ized with fever and ecchymoses. Her CSF was turbid with 900
leukocytes per µL, and N. meningitidis was confirmed by cul-
ture. She was treated with cefotaxime and made a full recov-
ery. Her father had returned from the Hajj 2 weeks before her
onset of symptoms, but apart from a cough and cold, he had
been clinically well. However, meningococcus was isolated
from his oropharynx, as well as from the throat of the patient’s
2-year-old brother. Isolates from the patient and her father and
brother were positive by agglutination with meningococcus
ACYW135 polyvalent reagent and negative with monovalent
sera for meningococcus A, B, and C.
The pilgrim’s vaccination certificate confirmed that he had
received a quadrivalent meningococcal vaccine. All three iso-
lates were sent to the WHO Collaborating Centre, which con-
firmed meningococcus serogroup W135, type 2a, subtype
1.2,5. They were indistinguishable by pulsed-field gel electro-
phoresis from isolates obtained from French pilgrims in 2000.
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Close contacts of all four patients with meningococcal dis-
ease received antimicrobial prophylaxis within 24 hours of
diagnosis: a single 500-mg dose of ciprofloxacin was given to
adults, and 2 days of rifampicin (10 mg/kg twice a day) was
given to children. Close contacts of the infant (case 4) were
also given the quadrivalent meningococcal vaccine. The only
meningococcal carriage studies were conducted on some close
contacts of this infant. No case secondary to those reported
above is known to have occurred. 
Two of these patients had meningococcal disease that was
shown by typing to have been caused by the same W135 clone
isolated from pilgrims returning from the Hajj in 2000 and
2001. Case 2 was culture negative but epidemiologically
linked with a returning pilgrim and was probably caused by
the same clone. Case 3 was also culture negative, but antigen
tests indicated that infection was caused by meningococcus
group W135 or group Y.
Conclusions
Cases of W135 meningococcal disease in returning pil-
grims and their contacts have been reported in several coun-
tries following the Hajj of 2000 (1) and 2001 (2). In many
European countries, further cases later occurred in persons
with no history of close contact with a returning pilgrim (3).
About 16% of the Mauritian population are Muslims, and
approximately 1,800 and 2,200 pilgrims traveled from Mauri-
tius to Saudi Arabia for the Hajj in 2000 and 2001, respec-
tively. In 2000, Mauritian pilgrims received the bivalent A+C
meningococcal polysaccharide vaccine, but five Mauritians
reportedly died in Saudi Arabia of meningitis of unspecified
type. Cases of meningococcal disease in Mauritius itself
occurred 3 months after the pilgrims returned, a period that
coincided with the annual peak in upper respiratory tract infec-
tions (4). Viral upper respiratory tract infections are known to
increase the risk of meningococcal disease (5). After the infec-
tions were reported in 2000, the Mauritian government
decided to import a quadrivalent meningococcal polysaccha-
ride vaccine (Mencevax ACWY, SmithKline Beecham, Gen-
val, Belgium) for pilgrims attending the Hajj in 2001, and
almost all of them received that vaccine. Although no case of
meningitis was subsequently reported among these pilgrims,
case 4 suggests that some have become carriers of meningo-
coccus W135. 
Evidence indicates that the quadrivalent meningococcal
polysaccharide vaccine may not prevent asymptomatic
nasopharyngeal  infection with N. meningitidis serogroup
W135 (6). Prophylactic administration of antibiotics to return-
ing pilgrims may be indicated to reduce the risk for transmis-
sion to close contacts. A recent study in the United States
showed that 0.8% of 727 returning pilgrims in 2001 were car-
riers of W135 meningococcus, compared with none on depar-
ture (7). All these pilgrims are presumed to have received the
quadrivalent meningococcal vaccine. In view of the low car-
riage rate, administration of chemoprophylaxis to all returning
pilgrims was not recommended (7). However, these findings
may not be applicable to pilgrims from developing countries.
During the Hajj, pilgrims from poorer countries often live in
more overcrowded accommodations than those from more
affluent regions, which may increase the risk of droplet trans-
mission and result in higher rates of asymptomatic carriage. 
Because several countries do not have scheduled flights to
Saudi Arabia, many pilgrims travel on chartered airplanes,
which would facilitate the administration of prophylaxis at the
airport to returning pilgrims. The effectiveness of single-dose
oral ciprofloxacin (8) simplifies the task. The disadvantages of
ciprofloxacin prophylaxis must, however, be considered,
including the small risk for anaphylaxis-like reaction (9). The
growing problem of antibiotic-resistant organisms cannot be
ignored, as fluoroquinolone resistance in the related species N.
gonorrhoeae has already emerged in many places (10). Chil-
dren and pregnant women, who likely represent only a small
proportion of pilgrims, could be given intramuscular ceftriax-
one, but there is also a risk of anaphylaxis besides the disad-
vantages of parenteral therapy. The decision to administer
chemoprophylaxis to all returning pilgrims should therefore
depend on whether transmission of W135 meningococcus dur-
ing future pilgrimages continues. Information regarding con-
tinuing transmission would be useful before pilgrims return to
their homes. 
During Hajj 2001, many pilgrims, especially from devel-
oping countries, were unlikely to have received the quadriva-
lent vaccine. The Ministry of Health of Saudi Arabia has
recently specified that, beginning in 2002, pilgrims must have
been vaccinated with a quadrivalent vaccine (2). This require-
ment may reduce future transmission. However, if cases con-
tinue to occur, many countries should consider prophylaxis for
returning pilgrims. Clearly, surveillance for meningococcal
disease in general and serogroup W135 in particular will
remain important in the next few years. 
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